A Phase I Study of IMC-A12 (Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors.

Trial Profile

A Phase I Study of IMC-A12 (Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2014

At a glance

  • Drugs Cixutumumab (Primary) ; Temsirolimus
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 22 Mar 2014 Results of an analysis investigating the pharmacokinetic profile of temsirolimus presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 23 May 2012 Planned number of patients changed from 40 to 41 as reported by ClinicalTrials.gov (NCT00880282).
    • 28 Mar 2012 New source identified and integrated (Oregon Health and Science University; IRB00005341).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top